PURE SCIENTIFIC TECHNOLOGIES INC.

"…we make medicine work better for you."

March 2021

FORWARD LOOKING STATEMENT

This presentation may contain forward-looking statements relating to the future performance of Pure Scientific Technologies Inc. (“PST”). Forward-looking statements, specifically those concerning future performance and the achievement of operating profitability are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties include the market acceptance of PST's products and services; competition within the technology industry and the introduction of new entrants and/or products in PST’s markets; adverse changes in governmental regulations and policies affecting the technology industry; product development risks and risks of technological change; the risk of unanticipated expenses; and other risks and uncertainties all as described in PST’s business plan and offering documents. Readers are cautioned that the foregoing list of factors is not exhaustive. Although PST believes that the expectations conveyed by the forward-looking statements are reasonable based on information available to it on the date such forward-looking statements are made, no assurances can be given as to future results, levels of activity and achievements. All subsequent forward-looking statements, whether written or oral, attributable to PST or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. PST assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

MISSION

To develop and market innovative products based on its patent-pending technologies utilizing Heliox for needle-free delivery of pharmaceuticals and CBD directly into the lungs.

CORPORATE STRATEGY

- A development stage medical device company
- New patent-pending drug delivery system for pharmaceuticals and CBD
- User-friendly inhaler with Heliox as carrier gas
- Digitally measured dosage and pressure control
- More effective reaching target cells and distal portions of lungs
- A timely solution with broad applications for pulmonary conditions
- Experienced management team proven successful in pioneering development of brachytherapy seeds for prostate cancer

pureScientific technologies

BENEFITS OF HELIOX

- FDA-approved breathing gas, non-toxic, non-carcinogenic with history of use over many decades
- Comprised of Helium (He) and Oxygen (O2) typically in a ratio of 80:20 or 70:30
- Less dense than pure oxygen, it is more easily absorbed by the lungs
- Commercially available at low cost with minimal adverse effects
- An example: During acute asthma exacerbations, albuterol nebulized with Heliox (Left) leads to more significant improvement in spirometry compared with albuterol nebulized with oxygen (Right) because the lower-density Heliox improves albuterol deposition in the distal airways.



Because of the very low density of helium, there is better delivery of albuterol nebulized with Heliox (Left) compared with albuterol Nebulized with oxygen (Right) in the lungs.

PRODUCT OVERVIEW

- PST Closed Loop Heliox Inhaler
- More efficient delivery of FDA- approved pharmaceuticals and CBD into the lungs and bloodstream
- Uses Heliox as the carrier gas
- More comfortable respiratory treatment experience
- Bluetooth Connection to smartphone app
- Secure Data Storage on dosage, flow measurement, pressure, time and date of treatment
- Secure access by patient, caregiver and physician

pureScientific technologies

PST Closed Loop Heliox Inhaler



DEVELOPMENT STRATEGY

Two parallel development pathways utilizing its patent-pending technologies:

- ✓ The rapidly growing holistic cannabidiol (CBD) market, projected to his $16 Billion in the U.S. by 2025; inhaling is most effective way of obtaining CBD
- ✓ The huge market for treatment of lung diseases using FDA-approved pharmaceuticals, including asthma, chronic bronchitis, COPD, cancer and pulmonary pandemics

- Initial thrust is the creation of desktop and personal versions of inhalers for the CBD market
- CBD market offers great potential for near-term financial returns with minimal regulatory oversite
- Design and development knowledge gained from the CBD devices will be leveraged into new products for FDA-approved pharmaceuticals.



REGULATORY PATHWAY

- The U.S. Food and Drug Administration ("FDA") provides regulatory oversite and approval of new pharmaceuticals and medical devices
- Heliox is already approved for human use; natural occurring holistic compounds like CBD do not generally require FDA approval.
- Fusing two FDA approved products (Heliox and approved pharmaceuticals) eases approval pathway
- Potential application of FDA Section 510(k) could streamline approval process for the use of the PST Heliox inhaler
- Management team has considerable experience with the FDA approval process, having successfully obtained approval for a number of devices in less than one year from initial filing
- Efforts underway to identify and partner with researchers in academia, public and private health



CBD chemical structure

PURE SCIENTIFIC TECHNOLOGIES INC.

Phase I (Now Completed) – Technical Development / Prototype Development



PHASE 1 DEVELOPMENT COMPLETED

Incorporated April 29, 2020 under the laws of Nevada, PST has now completed its Phase 1 Development Program. This Phase comprised: (i) corporate organization;(ii) assembly of management team;(iii) raise of seed financing of $508,000, (iv)) filing of patents covering PST's technology; and (v) completion of a working prototype of PST's desktop heliox inhaler with successful laboratory testing as proof of concept. PST is now raising capital to move on to Phase 2 which includes further development and commercialization.

PURE SCIENTIFIC TECHNOLOGIES INC.

Phase I – Deliverables / On-Time and On Budget

- ✓ Proof of Concept – Functional Prototype

Functional Prototype -
Using Heliox 80/20

- ✓ Conceptual Models and Designs

Actual 3D printed models (Shells)
Based on Concept Design Drawings

PURE SCIENTIFIC TECHNOLOGIES INC.

2021+

Phase II – Product Development Goals



Pure Scientific Technologies Team



L. MICHAEL CUTRER

CEO, PRESIDENT & DIRECTOR

Mike Cutrer is a highly accomplished executive with extensive management and technical experience in the medical device field.

He was co-founder and served for eighteen years as President, CEO and a Director of North American Scientific, Inc. (“NASI”) (a NASDAQ company), a Los Angeles-based manufacturer of radioisotope products for the medical industry.

NASI was an early innovator that successfully developed and marketed brachytherapy seeds implanted for the treatment of prostate cancer.

IRWIN A. OLIAN

EXECUTIVE CHAIRMAN & DIRECTOR

Irwin Olian is a highly successful entrepreneur with a strong legal and finance background. He is a creative innovator and proven business leader. Over the past thirty years, he has leveraged his skills in strategic business planning, management, administration, finance and law with creative thought and innovation to provide leadership to a large number of emerging companies.

He has broad experience in fields ranging from medical devices to biotechnology to high technology to entertainment to mining. His activities have included serving as the CEO or member of senior management or a director of a number of public and private companies, acting as a senior business consultant and being a strategic, early stage investor.

PHILIP CACAYORIN

VP - TECHNOLOGY

Philip Cacayorin, serving as Vice President - Technology, brings his exceptional advanced mathematics, physics and computer engineering skills to bear on development, fabrication and marketing of our new line of products utilizing the Company’s patent pending infusion technologies employing Heliox and helium as integral components of delivery systems for CBD and various pharmaceuticals directly into the lungs.

LEE DUNSTON

DIRECTOR OF CORPORATE COMMUNICATIONS

Lee has thirty-three years experience in sales and marketing, IT, management and business development with a strong investor relations background. His professional approach and focus will be communicating the PST story to the investment industry.

His sales, marketing and business development experience includes working with Enterprise Resource Planning software solutions with Systems Software Associates, Oracle Corporation as well as Healthcare management technology and solutions with Integrated Business Systems and Services Inc.

Pure Scientific Technologies Team

MARY BALDAUF M.D.

OUTSIDE DIRECTOR

Dr. Mary Baldauf has been practicing Medicine for 26 years. Her specialty is Pediatric Critical Care Medicine. As a physician working in an Intensive Care Unit, Dr. Baldauf uses highly developed technologies such as Nitric Oxide and Heliox in the treatment of critically ill patients. She has extensive experience in the areas of mechanical ventilation and advanced airway management.

As the founder of a medical technology company. Dr. Baldauf was granted patents for a variety of devices, including congenital heart defect models, therapeutic cushioning and devices for assisting respiration and administering fluid to patients. As a dedicated physician, Dr. Baldauf remains committed to furthering patient care through emerging technologies.

Dr. Baldauf received her undergraduate degree in Biology from Harvard University. She holds a Master of Science in Applied Human Physiology from the University of Health Sciences / Chicago Medical School. Dr Baldauf earned her Doctor of Medicine degree at the State University of New York.

.

MARTIN A. URBAN M.D., MMM

OUTSIDE DIRECTOR

Dr. Martin Urban is a highly experienced radiologist with extensive management and entrepreneurial skills, whose 30-year career covers the full range of interventional radiology, computed tomography and ultrasound.

In addition to his clinical experience, Marty brings 25 years management experience in the healthcare field, including ownership and management of a full-service freestanding imaging center and private practice radiology group. He has overseen patent filing and management and has a number of patents to his credit. He presently serves as Chairman of the Dept. of Medical Imaging at two hospitals in Illinois.

Marty received his Doctor of Medicine from Northwestern University Medical School and his Master of Medical Management from the University of Southern California. He has served as a Director of PST since March 2020.

.

CAPITAL STRUCTURE

Current Shares Issued and Outstanding:

10,500,000

<u>Seed Round Financing : June 2020</u>

$500,000 private placement

(2,500,000 shares at $0.20 per share)

<u>A Round Financing Scheduled for Q1 2021 to Raise $2.0 Million</u>

<u>The Company is Debt-Free</u>

pureScientific technologies

"…we make medicine work better for you."

THANK YOU

info@purescientifictech.com

https://www.purescientifictech.com

Pure Scientific Technologies Inc.
Irwin Olian (213) 300-3200
Irwin@purescientifictech.com